Graves' disease: diffuse enlargement of the thyroid
Conditions
Interventions
ATD treatment group:None
Second 131I treatment group:None
Sponsors
The first hospital of Shanxi Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Meets the diagnostic criteria for Graves' hyperthyroidism: (1) high metabolic symptoms and signs caused by increased sympathetic nervous activity, such as palpitations, sweating, and irritability; (2) diffuse enlargement of the thyroid gland (a few cases may have no thyroid enlargement); (3) decreased TSH levels and elevated FT4 levels; (4) positive serum TRAb. 2. Received 131I treatment for the first time. 3. Follow-up time of six months or more, with follow-up content including screening patients into hypothyroid or normal groups based on symptoms, signs, and serum thyroid hormone levels at the 6-month follow-up.
Exclusion criteria
Exclusion criteria: 1. Patients who have previously undergone thyroidectomy or ¹³¹I treatment; 2. Patients with hyperthyroidism caused by other reasons such as nodular goiter or autonomously functioning thyroid adenoma; 3. Pregnant and lactating women, or female patients planning pregnancy within 4–6 months; 4. Patients lost to follow-up or with incomplete clinical data; 5. Patients with granulocytopenia and/or severe liver and kidney dysfunction who cannot undergo clinical efficacy evaluation; 6. Patients diagnosed with or suspected of having thyroid cancer.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy of 131I treatment and thyroid function indicators (FT3, FT4, TSH); | — |
Countries
China
Contacts
Public ContactLu Keyi
The first hospital of Shanxi Medical University
Outcome results
None listed